From jewelers to health tech, CEOs want tariff refunds as earnings take a hit

Philips and Pandora said they will apply for tariff rebates after the Trump administration set up a refund portal following the Supreme Court's ruling that sweeping duties were illegal. Companies including BMW, Daimler, Renishaw, Smith & Nephew and Continental also flagged tariffs as a drag on first-quarter results, while Reuters cited a potential $175 billion U.S. redress bill and a first refund tranche expected by around May 11. The CNBC CFO survey suggests 12 of 25 CFOs plan to seek refunds, but none intend to cut prices for consumers.

Analysis

The immediate market implication is not a consumer windfall but a corporate balance-sheet event: tariff reimbursements function like an unplanned retroactive margin reset, and management teams will almost certainly treat them as non-recurring recoveries rather than a reason to reprice products. That creates a second-order effect where margin normalization in the next few quarters can look artificially better even if end-demand is unchanged, which should reduce the odds of broad-based deflation in imported discretionary goods.

For SNN specifically, the direct issue is less about the refund itself and more about whether tariff volatility is now another input that can be pushed through to hospitals and distributors without volume loss. Healthtech buyers tend to be stickier than consumers, so the tariff overhang is more likely to compress procurement timing than unit demand, creating a short-lived revenue hiccup followed by catch-up orders if rebates arrive. The cleaner read-through is that supplier exposure to U.S.-entry costs remains a planning risk for medtech names with complex cross-border manufacturing footprints, especially where pricing contracts are reset infrequently.

The bigger contrarian point is that refunds could actually be bearish for the inflation narrative in a narrow window while leaving realized consumer prices elevated. If companies keep the cash, the policy support is doing little for demand; if they redeploy it into capex, inventory, or debt paydown, the economy gets a modest business-sector stimulus without lower shelf prices. That favors firms with pricing power and global supply-chain flexibility, while punishing mid-cap industrials and healthtech vendors that can’t quickly re-architect sourcing if tariffs re-emerge in another legal form.

Key Decisions for Investors

• For SNN, stay underweight / hedge into the next 4-8 weeks: tariff reimbursement is a sentiment support, not a fundamental demand catalyst. Use any rebound tied to refund headlines to add downside protection via put spreads rather than chase upside.
• Pair trade: long pricing-power healthcare services / short tariff-exposed medtech assemblers over 1-3 months. The rebalance favors names that can pass through costs immediately versus names whose procurement and reimbursement cycles lag inflation.
• Buy volatility in European industrial/consumer importers over the next 30-60 days via straddles on names likely to keep litigating tariff exposure. The legal timing creates headline risk, but realized business impact will likely show up as guidance noise rather than a clean earnings beat.
• Avoid shorting broad retail solely on refund headlines. The more likely outcome is corporate retention of rebate cash, which is modestly disinflationary at the margin but not enough to change consumer spend behavior in the near term.
• If wanting a cleaner macro expression, prefer a long USD-quality beta basket versus import-intensive cyclicals for the next quarter; tariff uncertainty acts like a tax on inventory planning, capital efficiency, and forward guidance credibility.